The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 10, 2025

Filed:

Aug. 30, 2021
Applicant:

Biotheus Inc., Guangdong, CN;

Inventors:

Xiaoniu Miao, Guangdong, CN;

Cheng Chen, Guangdong, CN;

Zhijun Yuan, Guangdong, CN;

Weifeng Huang, Guangdong, CN;

Andy Tsun, Guangdong, CN;

Joanne Tsoyue Sun, Guangdong, CN;

Assignee:

BIOTHEUS INC., Guangdong, CN;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/46 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/468 (2013.01); A61P 35/00 (2018.01); C07K 2317/565 (2013.01);
Abstract

The present invention relates to the field of biomedicine and specifically relates to an anti-VEGF-anti-PD-L1 bispecific antibody, a pharmaceutical composition of same, and uses thereof. Specifically, the present invention relates to the bispecific antibody, which comprises: a VEGF-targeted first protein functional area and a PD-L1-targeted second protein functional area, wherein: the first protein functional area is an anti-VEGF antibody or an antigen-binding fragment thereof, or, the first protein functional area comprises a VEGF receptor or a fragment having a VEGF receptor function, and the second protein functional area is an anti-PD-L1 monoclonal antibody. The bispecific antibody of the present invention is capable of activating the immune system and blocking tumor angiogenesis at the same time, and provides great antitumor prospects.


Find Patent Forward Citations

Loading…